Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Combined With NALIRIFOX in Locally Advanced Pancreatic Cancer
NCT06429904Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Peking Union Medical College Hospital. Started May 2024; status: active, not recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06429904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429904.